Maurice Pérol
University of Lyon
292 Papers
1.2K Citations
Maurice Pérol is an academic researcher from University of Lyon. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 37, co-authored 241 publications.
Chat about Author
Papers
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon,Tudor Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N. Syrigos,Tuncay Göksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey Orlov,Conrad R. Lewanski,Michael Thomas,Paolo Bidoli,Shaker R. Dakhil,Steven J.M. Gans,Joo Hang Kim,Alexandru Grigorescu,Nina Karaseva,Martin Reck,Federico Cappuzzo,Ekaterine Alexandris,Andreas Sashegyi,Sergey Yurasov,Maurice Pérol +25 more
TL;DR: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC after platinum-based therapy and is registered with ClinicalTrials.gov.
1.2K
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares,Tudor-Eliade Ciuleanu,Manuel Cobo,Michael Schenker,B. Zurawski,Juliana Janoski de Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,O. Juan-Vidal,A. Alexandru,Hiroshi Sakai,Alejo Lingua,Pamela Salman,Pierre-Jean Souquet,Pedro Rafael Martins De Marchi,C. Martin,Maurice Pérol,Arnaud Scherpereel,Shun Lu,Thomas John,David P. Carbone,S. Meadows-Shropshire,Shruti Agrawal,Abderrahim Oukessou,J. Yan,Martin Reck +26 more
TL;DR: In this article, the authors investigated whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit of first-line nivolumab plus ipilimumab for advanced non-small-cell lung cancer (NSCLC).
1.1K
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Tony Mok,D.R. Camidge,Shirish M. Gadgeel,Rafael Rosell,Rafal Dziadziuszko,Dai Woo Kim,Maurice Pérol,S-H.I. Ou,Joonghyun Ahn,Alice T. Shaw,Walter Bordogna,Vlatka Smoljanovic,Magalie Hilton,Thorsten Ruf,Johannes Noe,Solange Peters +15 more
TL;DR: The publisher regrets that this article has been temporarily removed and a replacement will appear as soon as possible in which the reason for the removal will be specified.
537
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay,Jacques Cadranel,Amélie Lusque,Nicolas Meyer,Valérie Gounant,Denis Moro-Sibilot,Jean-Marie Michot,Judith Raimbourg,Nicolas Girard,Florian Guisier,David Planchard,Anne-cecile Metivier,Pascale Tomasini,Eric Dansin,Maurice Pérol,Marion Campana,Oliver Gautschi,Martin Früh,Jean-David Fumet,Clarisse Audigier-Valette,Sébastien Couraud,Stéphane Dalle,Marie-Thérèse Leccia,M. Jaffro,Samia Collot,G. Prévot,Julie Milia,Julien Mazieres +27 more
TL;DR: The main features of ICI–ILD are reported with a focus on clinical presentation, radiological patterns and therapeutic strategies, and oncologists need to diagnose and adequately treat this adverse event.
378
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Shirish M. Gadgeel,Solange Peters,Tony Mok,Alice T. Shaw,Dong Wan Kim,S-H.I. Ou,Maurice Pérol,Anna Wrona,Silvia Novello,Rafael Rosell,Ali Zeaiter,Ting Liu,Eveline Nüesch,Bogdana Balas,D.R. Camidge +14 more
TL;DR: Alectinib demonstrated superior CNS activity and significantly delayed CNS progression versus crizotinib in patients with previously untreated, advanced ALK+ NSCLC, irrespective of prior CNS disease or radiotherapy.
301